AnaptysBio, Inc. (ANAB)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$48.73+1.31%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge AnaptysBio, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	27.49M
EPS	—	5.11
Annual ending 2026-12-31
Revenue	—	138.05M
EPS	—	5.073
Annual ending 2027-12-31
Revenue	—	243.29M
EPS	—	6.749

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Achieve $390M in Jemperli royalties by 2029	AnaptysBio aims to reach $390 million in Jemperli royalties by 2029.	Intact	Jemperli royalties fail to grow toward $390 million by 2029	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 distinct disclosures including 2026-Q1 and 2026-09-21 press releases. Revenue from Jemperli royalties showed growth with collaboration revenue of $25.6 million in 2026-Q1 and $27.5 million in Q2 2026, reflecting 25-44% year-over-year growth in royalty streams. Management's trajectory remains consistent with expectations to exceed $390 million in annualized royalties by 2029, indicating delivery aligned with stated growth ambitions. Delivery assessment Oct 24, 2026
Stable and effective management team	A supporting condition in AnaptysBio, Inc.'s published investment case. The stated target is No major executive departures and steady progress on priorities.	Intact	Significant management turnover or failure to execute key initiatives	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Reach at least $390 million revenue in 2026	AnaptysBio aims to reach $390 million in Jemperli royalties by 2029.	Intact	Revenue falls below $390 million in FY26	Revenue: $27.488M FY2026-Q2; GAAP. Published target: >= $390 million. Target period is not explicitly aligned with this observation. Source published Sep 21, 202627,488,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: eeb7d929-9a0f-4350-8e4f-641a67dacd13. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 distinct disclosures including 2026-Q1 and 2026-09-21 press releases. Revenue from Jemperli royalties showed growth with collaboration revenue of $25.6 million in 2026-Q1 and $27.5 million in Q2 2026, reflecting 25-44% year-over-year growth in royalty streams. Management's trajectory remains consistent with expectations to exceed $390 million in annualized royalties by 2029, indicating delivery aligned with stated growth ambitions. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPSUnavailable

$5.24 → Unavailable · observed estimates

FY2027 revenueUnavailable

$0.15B → Unavailable · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$5.24	$153,193,990	5 / 7
2026-07-25	$5.24	$153,193,990	5 / 7
2026-07-26	$5.24	$153,193,990	5 / 7
2026-07-27	$5.24	$153,193,990	5 / 7
2026-07-28	$5.24	$153,193,990	5 / 7
2026-07-29	$5.24	$153,193,990	5 / 7
2026-07-30	$5.24	$153,193,990	5 / 7
2026-07-31	$5.24	$153,193,990	5 / 7
2026-08-01	$5.24	$153,193,990	5 / 7
2026-08-02	$5.24	$153,193,990	5 / 7
2026-08-03	$5.24	$153,193,990	5 / 7
2026-08-04	$5.24	$153,193,990	5 / 7
2026-08-05	$5.24	$153,193,990	5 / 7
2026-08-06	$5.24	$153,193,990	5 / 7
2026-08-07	$1.96	$153,194,993	5 / 5
2026-08-08	$5.24	$153,193,990	5 / 7
2026-08-09	$5.24	$153,193,990	5 / 7
2026-08-10	$5.24	$153,193,990	5 / 7
2026-08-11	$5.24	$153,193,990	5 / 7
2026-08-12	$5.24	$153,193,990	5 / 7
2026-08-13	$5.24	$153,193,990	5 / 7
2026-08-14	$1.96	$153,194,993	5 / 5
2026-08-15	$1.96	$153,194,993	5 / 5
2026-08-16	$1.96	$153,194,993	5 / 5
2026-08-17	$1.96	$153,194,993	5 / 5
2026-08-18	$1.96	$153,194,993	5 / 5
2026-08-19	$1.96	$153,194,993	5 / 5
2026-08-20	$1.96	$153,194,993	5 / 5
2026-08-21	$1.96	$153,194,993	5 / 5
2026-08-22	$1.96	$153,194,993	5 / 5
2026-08-23	$1.96	$137,780,464	5 / 5
2026-08-24	$1.96	$137,780,464	5 / 5
2026-08-25	$1.41	$131,351,344	5 / 5
2026-08-26	$1.41	$131,351,344	5 / 5
2026-08-27	$1.41	$131,351,344	5 / 5
2026-08-28	$1.41	$131,351,344	5 / 5
2026-08-29	$1.41	$131,351,344	5 / 5
2026-08-30	$1.41	$103,810,850	5 / 5
2026-08-31	$1.41	$103,810,850	5 / 5
2026-09-01	$1.41	$103,920,500	5 / 5
2026-09-02	$1.41	$103,920,500	5 / 5
2026-09-03	$1.41	$103,920,500	5 / 5
2026-09-04	$2.86	$136,160,667	5 / 5
2026-09-05	Unavailable	$136,160,667	4 / 5
2026-09-06	Unavailable	$136,160,667	4 / 5
2026-09-07	Unavailable	$136,160,667	4 / 5
2026-09-08	Unavailable	$136,160,667	4 / 5
2026-09-09	Unavailable	$136,160,667	4 / 5
2026-09-10	Unavailable	$136,160,667	4 / 5
2026-09-11	Unavailable	$158,486,157	4 / 5
2026-09-12	Unavailable	$158,486,157	4 / 5
2026-09-13	Unavailable	$158,486,157	4 / 5
2026-09-14	Unavailable	$158,486,157	4 / 5
2026-09-15	Unavailable	$158,486,157	4 / 5
2026-09-16	Unavailable	Unavailable	4 / 4
2026-09-17	Unavailable	Unavailable	4 / 4
2026-09-18	Unavailable	Unavailable	4 / 4
2026-09-19	Unavailable	Unavailable	4 / 4
2026-09-20	Unavailable	Unavailable	4 / 4
2026-09-21	Unavailable	Unavailable	4 / 4
2026-09-22	Unavailable	Unavailable	4 / 4
2026-09-23	Unavailable	Unavailable	4 / 4
2026-09-24	Unavailable	Unavailable	4 / 4
2026-09-25	Unavailable	Unavailable	3 / 4
2026-09-26	Unavailable	Unavailable	3 / 4
2026-09-27	Unavailable	Unavailable	3 / 4
2026-09-28	Unavailable	Unavailable	3 / 4
2026-09-29	Unavailable	Unavailable	3 / 4
2026-09-30	Unavailable	Unavailable	3 / 4
2026-10-01	Unavailable	Unavailable	3 / 4
2026-10-02	Unavailable	Unavailable	3 / 4
2026-10-03	Unavailable	Unavailable	3 / 4
2026-10-04	Unavailable	Unavailable	3 / 4
2026-10-05	Unavailable	Unavailable	3 / 4
2026-10-06	Unavailable	Unavailable	3 / 4
2026-10-07	Unavailable	Unavailable	3 / 4
2026-10-08	Unavailable	Unavailable	3 / 4
2026-10-09	Unavailable	Unavailable	3 / 4
2026-10-10	Unavailable	Unavailable	3 / 4
2026-10-11	Unavailable	Unavailable	3 / 4
2026-10-12	Unavailable	Unavailable	3 / 4
2026-10-13	Unavailable	Unavailable	3 / 4
2026-10-14	Unavailable	Unavailable	3 / 4
2026-10-15	Unavailable	Unavailable	3 / 4
2026-10-16	Unavailable	Unavailable	3 / 4
2026-10-17	Unavailable	Unavailable	3 / 4
2026-10-18	Unavailable	Unavailable	3 / 4
2026-10-19	Unavailable	Unavailable	3 / 4
2026-10-20	Unavailable	Unavailable	3 / 4
2026-10-21	Unavailable	Unavailable	3 / 4
2026-10-22	Unavailable	Unavailable	3 / 4
2026-10-23	Unavailable	Unavailable	3 / 4
2026-10-24	Unavailable	Unavailable	3 / 4

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	11	1
2026-06-01	11	0
2026-07-01	11	0
2026-08-01	11	0
2026-09-01	11	0
2026-10-01	8	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 8 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades1 maintains

Recent actions · Sep 25–Oct 24 · 1 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Achieve $390M in Jemperli royalties by 2029Direct metric needs a verified mapping
Stable and effective management teamDirect metric needs a verified mapping
Reach at least $390 million revenue in 2026Revenue: $27.488M

Next proof point

Nov 3, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.8%Typical daily move · historical

Downside history

-34.9%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

AnaptysBio, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a high-risk biotechnology business with a growth thesis tied in part to Jemperli royalties. The thesis is currently intact, though recent execution has been uneven and the next earnings report carries meaningful uncertainty.

What's priced into AnaptysBio, Inc.

The valuation is described as cheap versus peers, while the overall value view is neutral and confidence in the valuation model is low. The evidence suggests weak execution quality is recognized, but does not indicate that the full combination of high valuation, weak execution, and turbulence is priced in.

What the fundamentals likely do

Near term, Jemperli collaboration revenue has grown year over year, and management continues to pursue annualized royalties above $390 million by 2029. The First Tracks spin-off is complete, but earnings quality remains fragile, management is rated volatile, and erratic surprises create a notable risk of a miss or guidance cut at the next report.

What AnaptysBio, Inc. hinges on

The multi-year view depends on continued Jemperli royalty growth and management delivering on its stated priorities. Near term, a guidance cut or further labor-market weakness could weigh on cyclical healthcare businesses, while continued strong results and guidance from sector bellwethers could support sector momentum.